Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Medical Oncology • Hematology • ASH 2023
What are your top takeaways from ASH 2023?
Answer from: at Academic Institution
Gene therapy for sickle cell disease and beta thalassemia.
This was the first approval of CRISPR/Cas-based therapy in humans. Ex-vivo engineering of isologous hematopoietic stem cells followed by their reinfusion after myeloablative conditioning led to induction of 40-50% fetal hemoglobin in patien...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
IsKia study: Best MRD negativity rates of any front-line study especially for high risk myeloma.
PEGASUS study: Randomized Phase 3 study confirms findings from GRIFFIN study showing superiority of 4-drug vs 3-drug combo prior to transplant.
Talquetamab + pomalidomide in myeloma: first trial...
Answer from: Medical Oncologist at Community Practice
MDS and AML1. Abstract 319: Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes.Using the recommended phase 2 dose schedule (regimen including 14 days of venetoclax in each 28-day cycle), upfront ...
Answer from: at Academic Institution
The best presentation was the IRON REVOLUTION (Auerbach, DeLoughery, Powers): Lots of new, clarifying, and dispelled errors of the past.
The most inciteful presentation was the siRNA based therapeutics targeting VWD mutated genes as a new therapeutic, by Jeroen Eikenboom. This was in Denise Sabat...
Answer from: at Academic Institution
1. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the PERSEUS TrialThe results of t...
Answer from: Medical Oncologist at Community Practice
MANIFEST-2 One of the largest trials ever done in this disease, MANIFEST-2 enrolled 431 patients with JAK inhibitor-naïve, DIPSS intermediate-1 (60%), intermediate-2 (30%), or high risk (10%) myelofibrosis. Patients were randomly assigned (1:1) to receive ruxolitinib and pelabresib (BET inhib...
Answer from: at Academic Institution
Abstract 970 - A Phase IIb trial investigating intensive chemotherapy in comparison to hypomethylating agent + venetoclax in younger adults with newly diagnosed AML. The primary endpoint of CR/CRi was higher in the HMA + Venetoclax cohort which stimulates further discussion about which patients be...